Riddler Sharon A, Aga Evgenia, Bosch Ronald J, Bastow Barbara, Bedison Margaret, Vagratian David, Vaida Florin, Eron Joseph J, Gandhi Rajesh T, Mellors John W
University of Pittsburgh, Pennsylvania.
Center for Biostatistics in AIDS Research, Harvard School of Public Health.
J Infect Dis. 2016 Feb 15;213(4):556-60. doi: 10.1093/infdis/jiv433. Epub 2015 Sep 2.
We measured plasma human immunodeficiency virus type 1 (HIV-1) RNA levels by means of single-copy assay in 334 participants receiving virologically suppressive antiretroviral therapy (ART). A residual viremia load of ≥1 copy/mL after 4 years of ART was predicted by a higher pre-ART HIV-1 RNA level, higher CD8(+) T-cell count during treatment, and a lower ratio of CD4+ T cells to CD8+ T cells during treatment but not by initial ART regimen. In a longitudinal subset of 64 individuals, continued decay of the plasma HIV-1 RNA level was observed, with an average annual decrease of 6% and an estimated half-life of 11.5 years. In contrast to prior reports, the persistent viremia level continues to slowly decline during years 4-12 of suppressive ART.
NCT00001137.
我们通过单拷贝检测法测量了334名接受病毒学抑制性抗逆转录病毒疗法（ART）的参与者的血浆1型人类免疫缺陷病毒（HIV-1）RNA水平。ART治疗4年后残余病毒血症负荷≥1拷贝/毫升可通过ART治疗前较高的HIV-1 RNA水平、治疗期间较高的CD8(+) T细胞计数以及治疗期间较低的CD4+ T细胞与CD8+ T细胞比例预测，但与初始ART方案无关。在64名个体的纵向子集中，观察到血浆HIV-1 RNA水平持续下降，平均每年下降6%，估计半衰期为11.5年。与先前的报告相反，在抑制性ART治疗的第4至12年期间，持续的病毒血症水平继续缓慢下降。
NCT00001137。
